Condition: Metabolic Dysfunction-associated Steatotic Liver Disease · Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.
This description comes directly from the study's public registry record.
Guillaume Henin, MD, PhD student · 0032494312548 · guillaume.henin@uclouvain.be
Nicolas Lanthier, MD, PhD · 003227647089 · nicolas.lanthier@saintluc.uclouvain.be
Always discuss trial participation with your own doctor first.
| Cliniques universitaires Saint-Luc | Brussels, Belgium | Recruiting |
| Centre d'investigation clinique en nutrition | Louvain-la-Neuve, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06506513